From fecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy: how far down the road are we?

Key Points

• To investigate the timing and method of fecal microbiota transplants (FMT) for enhancing immune checkpoint inhibition (ICI) therapy.
• Assess FMT effectiveness in relation to ICI therapy timing.
• Evaluate benefits of microbiota consortia over donor-derived FMT.
• Focus on ICI naive patient population.
• FMT shows potential to enhance ICI therapy effects.
• Preferred microbiota consortia may yield better outcomes than traditional donor-derived FMT.
• Optimal treatment plan involves initial FMT before ICI administration.